Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing–remitting multiple sclerosis in Iranian patients

Loading...
Thumbnail Image
File version
Author(s)
Arababadi, Mohammad Kazemi
Mosavi, Reza
Khorramdelazad, Hossein
Yaghini, Narges
Zarandi, Ebrahim Rezazadeh
Araste, Majid
Pourali, Reza
Nekhei, Zohre
Kennedy, Derek
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2010
Size
90805 bytes
File type(s)
application/pdf
Location
License
Abstract

Background and aim: Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This project aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-? formulations in MS patients. Material and methods: In this study, blood samples were collected from 70 MS patients undergoing four different types of IFN-? formulation treatment and 100 healthy controls. After 24 months of treatment the serum levels of IL-17A, IL-12 and IFN-g and IL-10 in patients and healthy controls were analyzed by ELISA. Finding: Our results showed that serum levels of IL-17A were significantly higher in patients treated with Cinnovex and Anovex when compared to healthy controls. Serum levels of IL-10 were significantly decreased after therapy with Cinnovex, whereas serum levels of IFN-? were elevated. No difference in serum levels of IL-12 were detected in patients and controls. Conclusion: Results of our study suggest that Cinnovex and Anovex modulate the immune system less than Rebif and Betaferon in MS patients and that an elevated dosage/regime of Cinnovex and Anovex may be required for better regulation of the immune system in MS patients.

Journal Title
Biomarkers in Medicine
Conference Title
Book Title
Edition
Volume
4
Issue
5
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2010 Future Medicine Ltd. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal website for access to the definitive, published version.
Item Access Status
Note
Access the data
Related item(s)
Subject
Medicinal and biomolecular chemistry
Medical biochemistry and metabolomics
Clinical sciences
Medical genetics (excl. cancer genetics)
Persistent link to this record
Citation
Collections